Thrombectomy Devices Market to Surpass US$ 1.9 billion by 2026 - Coherent Market Insights

The Global Thrombectomy Devices Market, by Product Type (Mechanical Thrombectomy Devices, Aspiration Thrombectomy Devices, Hydrodynamic Thrombectomy Devices, and Ultrasonic Thrombectomy Devices), by Application (Neurovascular, Cardiovascular, and Peripheral Vascular), and by End User (Hospitals, Ambulatory Surgical Centers, and Research Laboratories and Academic Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 1.03 billion in 2017, and is projected to exhibit a CAGR of 7.4% during the forecast period (2018 - 2026).

 Thrombectomy procedure is indicated for patients with acute ischemic stroke caused due to blockage in one or more large arteries in the brain. People already treated with intravenous thrombolysis that has not been effective, can also be treated with the help of thrombectomy procedures. Thrombectomy approaches have evolved rapidly due to rising technological advancements of catheters as well as thrombectomy device such as intra-arterial thrombolytic infusions, which enable higher recanalization rates than before. Manufacturers are focused on gaining maximum product approval and innovating existing products in order to gain market share. In May 2018, Stryker Corporation received an expanded CE Mark approval in the European Union for its Trevo thrombectomy device as a front-line treatment for acute ischemic stroke patients. In August 2018, NexGen Medical Systems, Inc., completed the first human use of their XCOIL Large Vessel (18mm) Thrombectomy System for the treatment of deep vein thrombosis (DVT). The new device, an expansion of the successful XCOIL 12mm System, is designed to rapidly remove blood clots in large vessels, such as the iliac vein. In May 2017, SurModics acquired Embolitech’s thrombectomy platform and the associated intellectual property in a deal worth US$ 5 million, with additional payments based on regulatory milestones.

Browse 30 Market Data Tables and 33 Figures spread through 194 Pages and in-depth TOC on "Thrombectomy Devices Market, by Product Type (Mechanical Thrombectomy Devices, Aspiration Thrombectomy Devices, Hydrodynamic Thrombectomy Devices, and Ultrasonic Thrombectomy Devices), by Application (Neurovascular, Cardiovascular, and Peripheral Vascular), and by End User (Hospitals, Ambulatory Surgical Centers, and Research Laboratories and Academic Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026"

To know the latest trends and insights related to thrombectomy devices market, click the link below:

https://www.coherentmarketinsights.com/market-insight/thrombectomy-devices-market-2254

Key Takeaways of the thrombectomy devices Market:

• The global thrombectomy devices market is expected to expand at a CAGR of 7.4% during the forecast period (2018–2026), owing to increasing incidence of stroke and thrombosis, and rising technological advancement in thrombectomy devices. For instance, in 2016, Penumbra Inc., announced the U.S. commercial availability of its most advanced thrombectomy device, ACE68 Reperfusion Catheter. The product leverages the latest advancements in tracking technology to deliver maximum aspiration power easily and safely for extracting thrombus in acute ischemic stroke patients.
• Major players operating in the global thrombectomy devices market include Applied Medical, Argon Medical Devices, Inc., Boston Scientific Corporation, BTG International, Capture Vascular, Claret Medical, Control Medical Technology, Edwards Lifesciences Corporation, Johnson & Johnson, Medtronic PLC, Merit Medical Systems, Inc., Minnetronix, Inc., Nexgen Medical Systems, Inc., Natec Medical Ltd., Penumbra, Inc., Phenox GmbH, Stentys SA, Spectranetics Corporation, Straub Medical AG, Stryker Corporation, Terumo Corporation, and Teleflex Incorporated.